Skip to Main Content

Paper Details

Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
0
2023
Glucagon receptor, type 1 diabetes, volagidemab

Datasets

Release 1.2